open access

Vol 57, Supp. A (2006)
Original papers
Published online: 2006-09-25
Submitted: 2013-02-15
Get Citation

Assessment of the quality of life in patients with differentiated thyroid carcinoma during a one-month withdrawal of levorotatory thyroxine preparations (L-T4) before a control diagnostics

Monika Szymonek, Iwona Pałyga, Danuta Gąsior-Perczak, Aldona Kowalska

open access

Vol 57, Supp. A (2006)
Original papers
Published online: 2006-09-25
Submitted: 2013-02-15

Abstract

Introduction: Monitoring of patients with differentiated thyroid carcinoma consists of a periodic control for thyroglobulin (Tg) concentration and radioiodine diagnostics during stimulation of endogenous TSH. Application of recombinant TSH is an alternative procedure which considerably increases cost of diagnostics but allows to avoid symptoms of hypothyreosis. This work was aimed at evaluating the influence of a withdrawal of L-T4 preparations preceding the control diagnostics on the quality of life in patients.
Material and methods: Investigation was performed in a group of 131 patients [115 women (87.75%) and 16 men (12.25%)] with differentiated thyroid carcinoma admitted for a periodic control diagnostics that included neck ultrasonography and an evaluation of Tg concentration, wholebody scintigraphy following a stimulation of endogenous TSH after a one-month break in taking L-T4 preparations. Research was conducted with a prepared questionnaire assessing several basic determinants of the quality of life on a 6-degree scale.
Results: During hypothyreosis quality of life in patients with differentiated thyroid carcinoma is worsened. The frequency and volume of symptoms increased twice.
Conclusions: 1. One-month gap in taking L-T4 is associated with a significant deterioration of the quality of life in tested patients.
2. The symptoms are especially strongly expressed in the elderly.
3. Administration of recombinant TSH (rhTSH) for a control diagnostics may permit the patients with differentiated thyroid carcinoma to avoid a deterioration of the quality of life.

Abstract

Introduction: Monitoring of patients with differentiated thyroid carcinoma consists of a periodic control for thyroglobulin (Tg) concentration and radioiodine diagnostics during stimulation of endogenous TSH. Application of recombinant TSH is an alternative procedure which considerably increases cost of diagnostics but allows to avoid symptoms of hypothyreosis. This work was aimed at evaluating the influence of a withdrawal of L-T4 preparations preceding the control diagnostics on the quality of life in patients.
Material and methods: Investigation was performed in a group of 131 patients [115 women (87.75%) and 16 men (12.25%)] with differentiated thyroid carcinoma admitted for a periodic control diagnostics that included neck ultrasonography and an evaluation of Tg concentration, wholebody scintigraphy following a stimulation of endogenous TSH after a one-month break in taking L-T4 preparations. Research was conducted with a prepared questionnaire assessing several basic determinants of the quality of life on a 6-degree scale.
Results: During hypothyreosis quality of life in patients with differentiated thyroid carcinoma is worsened. The frequency and volume of symptoms increased twice.
Conclusions: 1. One-month gap in taking L-T4 is associated with a significant deterioration of the quality of life in tested patients.
2. The symptoms are especially strongly expressed in the elderly.
3. Administration of recombinant TSH (rhTSH) for a control diagnostics may permit the patients with differentiated thyroid carcinoma to avoid a deterioration of the quality of life.
Get Citation

Keywords

differentiated thyroid carcinoma; quality of life; rh-TSH

About this article
Title

Assessment of the quality of life in patients with differentiated thyroid carcinoma during a one-month withdrawal of levorotatory thyroxine preparations (L-T4) before a control diagnostics

Journal

Endokrynologia Polska

Issue

Vol 57, Supp. A (2006)

Pages

65-70

Published online

2006-09-25

Keywords

differentiated thyroid carcinoma
quality of life
rh-TSH

Authors

Monika Szymonek
Iwona Pałyga
Danuta Gąsior-Perczak
Aldona Kowalska

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl